Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
346 questions in 59 reviews · Vascular
current versionsNo studies 346 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
[Dorsalis pedis] B‐mode ultrasound guidance vs palpation and landmarks Pseudoaneurysm · adults requiring dorsalis pedis artery catheterisation Ultrasound guidance for arterial (other than femoral) catheterisation in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs no exercise Number of days on a ventilator · adults with clinically diagnosed AAA deemed suitable for elective repair Prehabilitation exercise therapy before elective abdominal aortic aneurysm repair (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time to ulcer healing · participants with arterial ulcersa Dressings and topical agents for arterial leg ulcers (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient satisfaction and quality of life data · participants with arterial ulcersa Dressings and topical agents for arterial leg ulcers (2020) · Cochrane | no estimate extracted | NR | No studies |
Atherectomy vs balloon angioplasty with primary stenting Primary patency ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Atherectomy vs balloon angioplasty with primary stenting Primary patency ( · people with PAD Atherectomy for peripheral arterial disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Angioplasty vs primary stenting Improvement in walking distance as reported by the patient · patients with symptomatic Iliac artery lesions Angioplasty versus stenting for iliac artery lesions (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs with active control (1) Major bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs with active control (1) Symptomatic DVT · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs with active control (1) 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs with active control (1) Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (2) Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (2) 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (2) Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (3) Major bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (3) Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (3) 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Low‐molecular‐weight heparin vs active control (3) Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs no thromboprophylaxis Symptomatic VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs no thromboprophylaxis Major bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs no thromboprophylaxis Symptomatic PE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs no thromboprophylaxis Symptomatic DVT · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs no thromboprophylaxis Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs placebo or no thromboprophylaxis Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs placebo or no thromboprophylaxis 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs placebo or no thromboprophylaxis Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs active control Any VTE · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs active control 1‐year overall mortality · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs active control Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Antithrombin vs no thromboprophylaxis Symptomatic VTE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Antithrombin vs no thromboprophylaxis Symptomatic PE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Antithrombin vs no thromboprophylaxis Symptomatic DVT · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Antithrombin vs no thromboprophylaxis 1‐year overall mortality · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Antithrombin vs no thromboprophylaxis Clinically relevant bleeding · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (2020) · Cochrane | no estimate extracted | NR | No studies |
Alternative modes of exercise vs walking exercise Health‐related QoL (at end of training, ranging from 12 to 24 weeks) · patients with IC Modes of exercise training for intermittent claudication (2020) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin (LMWH) vs no LMWH Complication and adverse reactions ‐ wound bleeding (analysed by participant, · patients undergoing digital replantation after traumatic amputation Low molecular weight heparin for prevention of microvascular occlusion in digital replantation (2020) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Incidence of compromised microcirculation requiring invasive intervention (re‐exploration) (analysed by participant/digit, · patients undergoing digital replantation after traumatic amputation Low molecular weight heparin for prevention of microvascular occlusion in digital replantation (2020) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Incidence of compromised microcirculation requiring invasive intervention (incision) (analysed by participant/digit, · patients undergoing digital replantation after traumatic amputation Low molecular weight heparin for prevention of microvascular occlusion in digital replantation (2020) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin (LMWH) vs no LMWH Success rate of replantation1 (analysed by participant) · patients undergoing digital replantation after traumatic amputation Low molecular weight heparin for prevention of microvascular occlusion in digital replantation (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Additional side effects of heparin · children with congenital heart disease undergoing CC Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac… (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs low molecular weight heparin Total VTE (fatal and non‐fatal) · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Heparin vs placebo Adverse events (timing not specified) · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs low molecular weight heparin PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs low molecular weight heparin All cause mortality · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs low molecular weight heparin Adverse events · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Unfractionated heparin vs low molecular weight heparin Bleeding (timing not specified) · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Heparin vs placebo Total VTE (fatal and non‐fatal) · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Heparin vs placebo DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity (2020) · Cochrane | no estimate extracted | NR | No studies |
Any pharmacological agent vs placebo or any other pharmacological agent Ulcer healing · patients with Buerger's disease Pharmacological treatment for Buerger's disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravenous prostacyclin analogue vs intravenous prostaglandin analogue Rate of amputation · patients with Buerger's disease Pharmacological treatment for Buerger's disease (2020) · Cochrane | no estimate extracted | NR | No studies |